New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
04:55 EDTJNJ, JNJ, SYK, SYK, NVDQ, NVDQ, COV, COV, CNMD, CNMD, ISRG, ISRGPiper Jaffray to hold booth tours
Booth Tours at SAGES Annual Meeting will be held in Salt Lake City, Utah on April 2-3.
News For JNJ;SYK;NVDQ;COV;CNMD;ISRG From The Last 14 Days
Check below for free stories on JNJ;SYK;NVDQ;COV;CNMD;ISRG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
15:00 EDTJNJWright Medical hip suit weakness would be buying opportunity, says Brean Capital
Subscribe for More Information
08:18 EDTCNMDCONMED urges holders to vote the GOLD proxy card
CONMED issued an open letter to its shareholders in connection with the company's September 10 Annual Meeting of Shareholders. CONMED's board unanimously recommends that shareholders follow the recommendations of leading proxy advisory firms Institutional Shareholder Services and Egan-Jones Proxy Services by voting "FOR" ALL of CONMED's eight director nominees as well as supporting the other proposals contained in the definitive proxy materials.
August 31, 2014
14:04 EDTJNJWorldwide Business Research to hold a conference
Subscribe for More Information
August 29, 2014
09:19 EDTCNMDCONMED says ISS, Egan-Jones recommends holders vote the GOLD proxy card
Subscribe for More Information
August 28, 2014
17:42 EDTJNJJ&J begins sales process for its medical device unit Cordis, WSJ says
Subscribe for More Information
12:30 EDTCNMDGlass Lewis supports Voce's call for further changes at CONMED
Subscribe for More Information
07:05 EDTCOVCovidien acquires Sapheon, terms not disclosed
Covidien announced that it has acquired Sapheon, Inc., a privately-held developer of venous disease treatments. Financial terms of the transaction were not disclosed.
August 26, 2014
19:33 EDTCOVCovidien shareholder sues to block sale to Medtronic, Bloomberg reports
Subscribe for More Information
07:22 EDTISRGISI Group to hold a field trip
Subscribe for More Information
August 25, 2014
08:27 EDTJNJJanssen Affiliate Cilag acquires Covagen, terms not disclosed
Subscribe for More Information
07:03 EDTJNJVIVUS acquires patents from Janssen Pharmaceuticals
VIVUS (VVUS) announced the acquisition of a group of patents from Janssen Pharmaceuticals (JNJ) covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.
August 22, 2014
07:01 EDTCOVCovidien acquires Reverse Medical, terms not disclosed
Subscribe for More Information
August 21, 2014
13:00 EDTISRGIntuitive Surgical receives FireFly FDA clearance for Vinci Xi system
Subscribe for More Information
05:42 EDTJNJIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
07:18 EDTCOVMedtronic shares have upside with or without deal, says Deutsche Bank
Deutsche Bank sees limited downside risk and significant upside potential for shares of Medtronic (MDT), with or without the pending Covidien (COV) acquisition. Deutsche says the Q1 results show improving trends and it keeps a Buy rating on Medtronic with an $85 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use